Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Terrosa

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Daily Brief: European approvals for BMS’ Opdivo, Aegerion’s lipodystrophy treatment, Pfizer’s biosimilar and Xeljanz

Will Pfizer spark price war with its Herceptin biosimilar?

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

- PMLiVE

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab’s OX40 candidate

The latest from pharma, biotech and healthcare

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

Ashfield and Sanofi scoop ICE award

Company wins the Most Effective Agency Collaboration Award for the second year running

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

- PMLiVE

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Speech coincides with Biosimilars Action Plan

- PMLiVE

Some pharma companies not prepared for Brexit, warns EMA

Regulator concerned about medicines shortages after March 2019

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links